
Annual report 2025
added 03-18-2026
InspireMD Revenue 2011-2026 | NSPR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue InspireMD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.98 M | 7.01 M | 6.2 M | 5.17 M | 4.5 M | 2.48 M | 3.72 M | 3.6 M | 2.76 M | 1.89 M | 2.31 M | 2.82 M | 4.87 M | 5.35 M | 6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.98 M | 1.89 M | 4.51 M |
Quarterly Revenue InspireMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.52 M | 1.78 M | 1.53 M | - | 1.81 M | 1.74 M | 1.51 M | - | 1.56 M | 1.65 M | 1.24 M | - | 1.43 M | 1.53 M | 1.18 M | - | 1.07 M | 1.04 M | 1.01 M | - | 980 K | 313 K | 1.03 M | - | 939 K | 1.35 M | 415 K | - | 769 K | 1 M | 1.01 M | - | 718 K | 640 K | 569 K | - | 469 K | 540 K | 563 K | - | 632 K | 685 K | 477 K | - | 273 K | 193 K | 1.48 M | - | 1.55 M | 1.5 M | 1.55 M | 1.35 M | 509 K | 1.86 M | 509 K | 1.29 M | 1.99 M | 1.04 M | 1.69 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.52 M | 193 K | 1.12 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.07 | 0.33 % | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
4 B | $ 171.87 | 0.74 % | $ 12.9 B | ||
|
AxoGen
AXGN
|
225 M | $ 32.64 | -5.23 % | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.13 | 0.49 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.74 | -0.05 % | $ 5.47 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.59 | -0.37 % | $ 92.7 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 10.97 | 1.29 % | $ 1.65 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | - | - | $ 1.06 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.38 | 0.11 % | $ 266 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.59 | 1.2 % | $ 36.7 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.7 | 0.73 % | $ 347 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.19 | 0.17 % | $ 47.5 B | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
64 M | $ 23.61 | 1.37 % | $ 200 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.6 | 0.05 % | $ 122 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 88.6 | 0.77 % | $ 12 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.9 | 2.15 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
349 M | $ 6.36 | 2.42 % | $ 169 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.14 | -1.55 % | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.0 | 1.66 % | $ 16.9 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 95.66 | -0.59 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.63 | -1.4 % | $ 2.97 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M |